MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES

High efficacy of contemporary chemical and radiation treatments made it to success in treatment of oncohematological diseases. The fundamentals of many schemes of polychemotherapy of the first line are anthracyclines. Effective treatment of the main disease in many cases is followed by a variety of cardiovascular  complications, including severe ones and fatal. It is necessary to consider the possibility not only for development  of acute cardiotoxicity, but various complications from cardiovascular system  after cessation of antitumor treatment. Algorithm of patients  preparing  for such treatment must include cardiovascular  assessment before the start of drugs, and follow-up during the treatment course. Prevention and treatment of cardiotoxicity are complicated clinical issues due to irreversible and progressing character of most disorders  of cardiovascular  system.  An important issue  is a close collaboration of cardiologist and oncologist in patient’s management. It is necessary to have longterm  dynamic  follow-up of  patients   after  chemotherapy  for  maximally early diagnostics   of cardiovascular   complications  in long-term  period  after  finishing of antitumor treatment.

1. Mareev VY, Ageev FT, Arutyunov GP, et al. National guidelines OSSN, the RKO and RNMOT for the diagnosis and treatment of chronic heart failure (fourth revision). Journal of Heart failure, 2013; 14, 7 (81). Russian (Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность, 2013; 14, 7 (81)).

2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. JACC 2013; 62, 16: e147-239.

3. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J., 2016; 37 (23): 1850-8. doi:10.1093/eurheartj/ehv727.

4. Zamorano JL, Lancellotti P, Munoz DR, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal doi:10.1093/eurheartj/ehw211.

5. Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol, 2010; 21 (5): 277-82.

6. Poddubnaya IV, Oriol NF. Guide for chemotherapy of neoplastic diseases. Ed. NI Perevodchikova. M., 2011: 435-6. Russian (Поддубная И. В., Орел Н. Ф. Руководство по химиотерапии опухолевых заболеваний. Под ред. Н. И. Переводчиковой. М., 2011: 435-6).

7. Hochhaus A, Kantarjian H. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol (2013) 139:1971-84 DOI 10.1007/s00432-013-1488-z.

8. Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. Journal of Clinical Oncology.2015 Dec 10; 33(35): 4210-8. doi: 10.1200/JCO.2015.62.4718.

9. Emelina EI, Gendlin GE. Cardiology problems in oncology practice. Oncohematology Journal, 2012; 2: 18-23. Russian (Емелина Е. И., Гендлин Г. Е. Проблемы кардиологии в онкологической практике. Журнал Онкогематология, 2012, 2: 18-23).

10. Matyas MG, Kravchuk TL, Vysotskaya VV, et al. Anthracycline-induced cardiotoxicity: mechanisms of development and clinical manifestations. Siberian Journal of Oncology 2008; 6 (30): 66-75. Russian (Матяш М. Г., Кравчук Т. Л., Высоцкая В. В. и др. Индуцированная антрациклинами кардиотоксичность: механизмы развития и клинические проявления. Сибирский онкологический журнал, 2008; 6(30): 66-75).

11. Vejpongsa P, Yeh ETH. Prevention of Anthracycline-Induced Cardiotoxicity. Challenges and Opportunities. Journal of the American College of Cardiology, 2014; 64, 9: 938-45.

12. The Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative disorders. Edited by prof. Poddubnaya IV, prof. Savchenko VG. М. Buki Vedi, 2016. Russian (Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под редакцией проф. Поддубной И. В., проф. Савченко В. Г. М. Буки Веди, 2016).

13. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines Сlinical practice guidelines. Annals of Oncology, 2012; 23 (7): 155-66.

14. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97: 2869-79.

15. Brana I, Tabernero J. Cardiotoxicity. Ann Oncol., 2010; 21(7): 173-9. doi: 10.1093/annonc/mdq295.

16. Raj S, Franco VI, Lipshultz SE. Anthracycline-Induced Cardiotoxicity: A Review of Pathophysiology, Diagnosis, and Treatment. Curr Treat Options Cardio Med, 2014; 16: 315.

17. Douraid KS, Kakil IR. Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management. J. Clin. Med Res., 2009; 1(1): 8-12.

18. Shuykova KV, Emelina EI, Gendlin GE, et al. Alteration of left ventricular function in patients with lymphoma during administration of anthracycline antibiotics. Russian Journal of Cardiology, 2016; 1 (129): 41-6. Russian (Шуйкова К. В., Емелина Е. И., Гендлин Г. Е. и др. Изменение функции левого желудочка сердца больных с лимфомами на фоне введения антрациклиновых антибиотиков. Российский кардиологический журнал, 2016; 1 (129): 41-6. doi.org/10.15829/1560-4071-2016-1-41-46).

19. Miolo GM, Mura NL, Nigri P, et al. The cardiotoxicity of chemotherapy: New prospects for an old problem. Radiol Oncol, 2006; 40(3): 149-61.

20. Lyu Y, Kerrigan JE, Lin CP, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007; 67: 8839-46.

21. Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol 2007; 25: 493-500.

22. Vrooman LM, Neuberg DS, Stevenson KE, et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer, 2011; 47: 1373-9.

23. Salzer WL, Devidas M, Carroll WL, et al. Longterm results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children’s oncology group. Leukemia, 2010; 24: 355-70.

24. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracyclineinduced cardiomyopathy. J Am Coll Cardiol, 2006; 48: 2258-62.

25. Pravdivtseva EV, Poteshkina NG, Svanadze AM, et al. Prevention of cardiotoxicity of the anthracycline antibiotic doxorubicin: the role of ACE inhibitor perindopril. Clinician.2011; 5, 3: 55-60. Russian (Правдивцева Е. В., Потешкина Н. Г., Сванадзе А. М. и др. Профилактика кардиотоксического действия антрациклинового антибиотика доксорубицина: роль ингибитора ангиотензинпревращающего фермента периндоприла. Клиницист. 2011; 5, 3: 55-60).

26. Bosch X, Rovira M, Sitges M, et al. Enalapril and Carvedilol for Preventing ChemotherapyInduced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies. The OVERCOME Trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). Journal of the American College of Cardiology 2013; 61, 23. ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.072.

27. Felker GM, Thompson RE, Hare JM, et al. Underlying Causes and Long-term Survival in Patients with Initially Unexplained Cardiomyopathy. The New England Journal of Medicine, 2000; 342, 15: 1077-84.

28. Lenneman AJ, Wang L, Wigger M, et al. Heart transplant survival outcomes for adriamycindilated cardiomyopathy. Am J Cardiol., 2013; 111: 609-12.

29. Oliveira GH, Qattan MY, Kindi SAl, et al. Advanced Heart Failure Therapies for Patients With Chemotherapy-Induced Cardiomyopathy. Circ Heart Fail., 2014; 7: 1050-8.

30. Schlitt A, Jordan K, Vordermark D, et al. Cardiotoxicity and oncological treatments. Dtsch Arztebl Int, 2014; 111(10): 161-8. DOI: 10.3238/arztebl.2014.0161.